Cargando…

Persistence of humoral and cellular immune response after SARS-CoV-2 infection: opportunities and challenges

Detalles Bibliográficos
Autor principal:	Wu, Tangchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585350/ https://www.ncbi.nlm.nih.gov/pubmed/33098549 http://dx.doi.org/10.1007/s11684-020-0823-4

Ejemplares similares

Realization of humoral immunity against SARS-CoV-2 infections
por: Lin, Yong, et al.
Publicado: (2021)

Persistent Cellular Immunity to SARS-CoV-2 Infection
por: Breton, Gaëlle, et al.
Publicado: (2020)

Persistent cellular immunity to SARS-CoV-2 infection
por: Breton, Gaëlle, et al.
Publicado: (2021)

Innate Immune Response in SARS-CoV-2 Infection
por: Schiuma, Giovanna, et al.
Publicado: (2022)

Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2
por: Taefehshokr, Nima, et al.
Publicado: (2020)

Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery
por: Feng, Chengqian, et al.
Publicado: (2021)

SARS-CoV-2 infection and the antiviral innate immune response
por: Yang, Hui, et al.
Publicado: (2020)

Cellular and humoral immunity in patients infected with the SARS-CoV-2 virus at general hospital
por: Brandão, Valéria, et al.
Publicado: (2021)

SARS-CoV-2–reactive cellular and humoral immunity in hemodialysis population
por: Anft, Moritz, et al.
Publicado: (2021)

Approaches and Challenges in SARS-CoV-2 Vaccine Development
por: Dagotto, Gabriel, et al.
Publicado: (2020)

Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
por: Schiffner, Julia, et al.
Publicado: (2021)

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
por: Pušnik, Jernej, et al.
Publicado: (2023)

Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
por: Gambichler, Thilo, et al.
Publicado: (2020)

The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages
por: Xiang, Tiandan, et al.
Publicado: (2022)

SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity
por: Kouamou, Vinie, et al.
Publicado: (2021)

Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity
por: Burtscher, Johannes, et al.
Publicado: (2020)

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
por: Netea, Mihai G., et al.
Publicado: (2020)

Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in children
por: Ruedas-López, Alba, et al.
Publicado: (2022)

Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19
por: Chivu‐Economescu, Mihaela, et al.
Publicado: (2022)

SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation
por: Sandberg, John Tyler, et al.
Publicado: (2021)

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS‐CoV‐2 vaccination
por: Hollstein, Moritz M., et al.
Publicado: (2022)

SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies
por: Haggenburg, Sabine, et al.
Publicado: (2022)

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
por: Murray, Sam M., et al.
Publicado: (2022)

Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge
por: Gary, Ebony N., et al.
Publicado: (2023)

Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men: Heterogenous immunity to SARS-CoV-2
por: Le Bert, Nina, et al.
Publicado: (2021)

Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity
por: Truong, Thao T., et al.
Publicado: (2021)

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2022)

Protective humoral immunity in SARS-CoV-2 infected pediatric patients
por: Zhang, Yaguang, et al.
Publicado: (2020)

Cross-reactive memory T cells and herd immunity to SARS-CoV-2
por: Lipsitch, Marc, et al.
Publicado: (2020)

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
por: Cromer, Deborah, et al.
Publicado: (2021)

A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity
por: Li, Yang, et al.
Publicado: (2022)

Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern
por: Ruhl, Louisa, et al.
Publicado: (2023)

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
por: Felten, Renaud, et al.
Publicado: (2022)

Superantigens and SARS-CoV-2
por: Hamdy, Adam, et al.
Publicado: (2022)

Impact of hypertension on long-term humoral and cellular response to SARS-CoV-2 infection
por: Chu, Chang, et al.
Publicado: (2022)

Role of the early secretory pathway in SARS-CoV-2 infection
por: Sicari, Daria, et al.
Publicado: (2020)

SARS-CoV-2 infections in children: Understanding diverse outcomes
por: Brodin, Petter
Publicado: (2022)

Improving Nasal Protection for Preventing SARS-CoV-2 Infection
por: Nocini, Riccardo, et al.
Publicado: (2022)

The Recombination Potential between SARS-CoV-2 and MERS-CoV from Cross-Species Spill-over Infections
por: Sajini, Abdulrahim A., et al.
Publicado: (2021)

Humoral Immune Response to SARS-CoV-2 in Iceland
por: Gudbjartsson, Daniel F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_unmgniho2oq7jt3q7b69rr8on5